Diagnostics In Brief
This article was originally published in The Gray Sheet
Executive Summary
BioNanomatrix, NCI collaborate: Genome imaging and analytic platform developer BioNanomatrix inks a multi-year research and development agreement with the National Cancer Institute, firm announces Jan. 18. The company will work with NCI's Radiation Biology Branch to develop tools to detect and quantify DNA damage caused by cancer therapies in order to optimize radiation dosing. BioNanomatrix's Nanoanalyzer whole genome analyzer unwinds DNA from its supercoiled structure to enable the identification of specific DNA aberrations. Pending successful results assessing radiation-induced damage, the firm plans to study DNA aberrations resulting from chemotherapy. BioNanomatrix has an exclusive license to use the technologies from Princeton University...
You may also be interested in...
Radiation Therapy Gets Personal: Diagnostic Tools Offer New Possibilities
Radiation therapy that tailors treatment to individual tumor characteristics is advancing, with both the market leader in radiation devices and a small start-up firm eyeing business opportunities
Radiation Therapy Gets Personal: Diagnostic Tools Offer New Possibilities
Radiation therapy that tailors treatment to individual tumor characteristics is advancing, with both the market leader in radiation devices and a small start-up firm eyeing business opportunities
Celera Shifts Focus To Clinical Diagnostics, Deserting Drug Development
Celera Genomics will shed its small-molecule drug development programs to focus on the development of diagnostic tests and discovering proteins useful to pharmaceutical manufacturers